Roche's Parkinson's drug, prasinezumab, has failed a Phase IIb trial, despite showing potential clinical efficacy in delaying motor progression. While the results indicated positive trends in secondary endpoints, they lacked statistical significance, prompting analysts to call the data "promising but leaves uncertainty." Roche plans to continue related studies and may consider a new trial to further explore the findings.
